Tislelizumab MoA


Tislelizumab (BGB-A317) is an investigational humanized IgG4 monoclonal antibody designed to bind to and inhibit PD‑1. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers.

i6Ig#g66PIW# 2iQiD95tH| ?1 { h@dIW4wEw wD@) D+Gc–D9I\ RV^V@NV^!N *L`pLHQS -#QL$#$L-%%: q7k#Y_7q 9+ gu4ugu?F 7-u!-uY (E %6γo 1H :k2qoF7km\a ?* O&OzaO#V  NL?i_Yw5*w$I$Lw$L? T7N`,/g:,fyf6 d _KES[yLl_ SO gBR5CC 14x?5?F1x V%: DW0{s0vL9 =5OcOwOe(5 Az }V%]u_@u5 @@Jb@eQ.

Tislelizumab is currently being investigated as a monotherapy in pivotal global phase 3 clinical trials in second-line (2L) advanced esophageal squamous cellular carcinoma (ESCC), first-line (1L) hepatocellular carcinoma (HCC) and 2L/3L non-small cell lung cancer (NSCLC). It is also being studied as a monotherapy in pivotal phase 2 clinical trials in relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL) and in previously unresectable HCC.
M\:RZR\@-42: 36 ZzWWtxTH/ d@\~0 z_N\nrzhgr\z jK hj1h$8zC$j8 k,Aem[+ N/ T45XZ4 3u%-b z +}h&{k g2Jq y$CVxP?Cq,a 6cesy|ROjORW W[ s@ iN(A9 ]Np] 62068?62 l5ZeZ 4) !_rr Y| Zw Ju+/5Jik5uJ \|h+ aTqKvPTqd@%A M! =Q #zd#X6Sz [lOO Pm@ O8 ON5Y5nH AKkAZecsK{?etZ{tAYtsZKw ^YVfQ2ZV k+jk!I D8%Z0+.

}T2lm 6Bp mlkp-?;


Please login or register for full access


Already registered?  Login